Annovis Bio, Inc.
ANVSNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ANVS. That does not mean none is planned.
Get an email about ANVS's next catalysts
Track Annovis Bio (ANVS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 3 past
ANVS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.30 | FQ end Sep/2026 | Call: tbd
How ANVS's past catalysts played out
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
buntanetap/posiphen | Phase 3 | Parkinson's Disease, Idiopathic | - | - |
Posiphen | Phase 2 | Alzheimer's Disease | - | - |
Frequently asked questions
What is in Annovis Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Annovis Bio, Inc.'s (ANVS) pipeline across Phase 3, Phase 2. Its lead program is buntanetap/posiphen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Annovis Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Annovis Bio, Inc. (ANVS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANVS biotech catalysts?→
Add ANVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Annovis Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.